导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 1.15% | 1933/4773 |
| 近一周 | -3.15% | 3775/5462 |
| 近一月 | -9.87% | 4902/5421 |
| 近一季 | -18.50% | 4712/5209 |
| 近半年 | -1.73% | 1677/4920 |
| 近一年 | 5.29% | 1619/4366 |
| 近两年 | 104.10% | 568/2954 |
| 近三年 | 60.34% | 438/2253 |
| 成立以来 | 133.79% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.86% 1995/4961 |
34.23% 962/5312 |
- - |
- - |
| 2025 | 47.23% 572/4813 |
-1.66% 2731/3635 |
3.04% 1193/4076 |
47.10% 488/4524 |
-1.22% 2871/4813 |
| 2024 | 13.38% 1143/3463 |
-3.48% 1509/2808 |
-6.43% 1944/3014 |
27.43% 224/3129 |
-1.48% 1719/3463 |
| 2023 | -18.05% 1779/2656 |
1.98% 1472/2280 |
-6.82% 1716/2385 |
-9.15% 1783/2515 |
-5.08% 1251/2655 |
| 2022 | -27.70% 1500/2207 |
-19.04% 1422/1919 |
5.78% 827/2016 |
-17.52% 1607/2113 |
2.35% 962/2208 |
| 2021 | 14.31% 339/1822 |
-5.78% 957/1255 |
25.56% 86/1330 |
-5.61% 834/1466 |
2.37% 610/1822 |
| 2020 | 64.45% 98/1250 |
4.56% 70/1028 |
28.43% 104/1067 |
6.39% 846/1164 |
15.11% 233/1184 |
| 2019 | 41.43% 230/1092 |
32.70% 166/739 |
-9.04% 628/788 |
7.22% 98/850 |
9.28% 238/918 |
| 2018 | - - |
- - |
- - |
- - |
-10.13% 179/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 华夏创业板ETF联接C VS. 长安沪深300非周期A(740101) |